New HER2-Targeting drug shows promise in early cancer trial
NCT ID NCT05872295
First seen Nov 01, 2025 · Last updated Jun 10, 2026 · Updated 30 times
Summary
This study tests IKS014, a drug designed to seek out and destroy HER2-positive cancer cells, in people with advanced solid tumors like breast, stomach, and gastroesophageal cancers. The main goals are to find the safest dose and check for early signs of tumor shrinkage. About 165 participants will receive the drug intravenously, and researchers will monitor side effects and how the body processes the treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Alfred Health
RECRUITINGMelbourne, Victoria, 3004, Australia
Contact Phone: •••-•••-••••
Contact
-
Auckland City Hospital
RECRUITINGAuckland, New Zealand
Contact
-
Concord Repatriation General Hospital Medical Oncology Clinical Trials Unit
RECRUITINGConcord, New South Wales, 2139, Australia
Contact Phone: •••-•••-••••
Contact
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact
-
Hoag Memorial Hospital Presbyterian
RECRUITINGNewport Beach, California, 92663, United States
Contact
-
Linear Clinical Research
RECRUITINGNedlands, Western Australia, 6009, Australia
Contact Phone: •••-•••-••••
Contact
-
Macquarie University
RECRUITINGSydney, New South Wales, 2109, Australia
Contact
-
National Cancer Centre Singapore
RECRUITINGSingapore, Singapore
Contact
-
Peninsula & South Eastern Haematology and Oncology Group (PSEHOG)
RECRUITINGFrankston, Victoria, 3199, Australia
Contact Phone: •••-•••-••••
Contact
-
START Dallas - Fort Worth
RECRUITINGFort Worth, Texas, 76104, United States
Contact
Contact Email: •••••@•••••
-
Tan Tock Seng Hospital
RECRUITINGSingapore, Singapore
Contact
-
Tennessee Oncology
RECRUITINGNashville, Tennessee, 37203, United States
Contact
-
Westmead Hospital
RECRUITINGWestmead, New South Wales, 2145, Australia
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.